BEVICRA 100MG contains Bevacizumab which belongs to a group of medicines called antiangiogenic agents. It is indicated to treat metastatic colorectal cancer, first-line non-squamous non small cell lung cancer, recurrent glioblastoma (GBM), metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer and hepatocellular carcinoma.
Bevacizumab is a humanized monoclonal IgG1 antibody which contains human framework regions and murine complementarity determining regions. This binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. This interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in invitro models of angiogenesis. Bevacizumab reduces microvascular growth and inhibition of metastatic disease progression.
Before receiving this BEVICRA 100MG, tell your physician if you have liver, kidney or heart problems, are pregnant or breastfeeding. This medicine is not suitable for use in children and adolescents below 18 years of age. The common side effects are nose or rectal bleeding, headache, back pain or increased blood pressure.
Treats,
Bevacizumab belongs to antiangiogenic agents which works by stopping the formation of blood vessels that bring oxygen and nutrients to tumors and slows the growth and spread of tumors.
BEVICRA 100MG will be administered as an intravenous infusion by your doctor or nurse.
Headache:
Rest and drink plenty of fluids. Apply a wet or cold cloth to forehead and rest in a quiet, comfortable, dark room.
Back pain:
Use an ice pack or over the counter medicines to relieve pain.
BEVICRA 100MG is not recommended for use in pregnant women unless necessary. Discuss the risks and benefits with your Doctor.
BEVICRA 100MG is not recommended for use in breastfeeding women unless necessary. Discuss the risks and benefits with your Doctor.
BEVICRA 100MG should be used with caution in patients suffering from kidney diseases. Consult your doctor for advice.
BEVICRA 100MG should be used with caution in patients suffering from liver function impairment or active liver diseases. Consult your doctor for advice.
Tell your doctor if you are allergic (hypersensitive) to Bevacizumab.
BEVICRA 100MG should be used with caution in patients suffering from chronic lung disease. Consult your doctor for advice.
BEVICRA 100MG should be used with caution in patients suffering from active heart diseases. Consult your doctor for advice.
Tell your doctor before taking this medicine if you have or had:
Tell your doctor if you are taking,
Drug | : | Bevacizumab |
Pharmacological Category | : | Antiangiogenic agents |
Therapeutic Indication | : | Metastatic colorectal cancer, First-line non-squamous non small cell lung cancer, Hepatocellular carcinoma |
Dosage Forms | : | Injection |
Can BEVICRA 100MG be used during pregnancy?
It is not suitable for use in pregnant women, unless prescribed by your doctor.
How BEVICRA 100MG works differently from chemotherapy?
It prevents the growth of new blood vessels that feed tumors and causes the tumour to shrink, or to stop growing.
How is BEVICRA 100MG given?
It will be administered intravenously by your doctor or nurse.
1. KD Tripathi MD. Anticancer drugs. Essentials of Medical Pharmacology 7th ed. New Delhi, May 2013. Page – 871.
2. Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. Page - 1739-1740.
3. Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. Page - 955.
4. Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. Page - 142-143.
5. Filis Kazazi-Hyseni, Jos H. Beijnen and Jan H. M. Schellens. Bevacizumab. Aug 15, 2010. [Accessed on June 16, 2021] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228024/
6. Genentech, Inc. 2004. [Revised on Jan, 2021] [Accessed on June 16, 2021] https://www.gene.com/download/pdf/avastin_prescribing.pdf
7. Abevmy. Oct 06, 2017. [Accessed on June 16, 2021] https://5.imimg.com/data5/CN/TA/HA/GLADMIN-112814/abevmy-cancer-injection.pdf
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.